Takeda and TiGenix Announce Publication in The Lancet of 24-Week Results of the Phase 3 ADMIRE-CD Trial Investigating Cx601 in the Treatment of Complex Perianal Fistulas in Patients with Crohn's Disease

OSAKA, Japan and LEUVEN, Belgium, Aug. 2, 2016 /PRNewswire/ -- Takeda Pharmaceutical Company Limited (TSE: 4502 ) ("Takeda") and TiGenix NV (Euronext Brussels: TIG) ("TiGenix") today announced that the 24-week results of the Phase 3 ADMIRE-CD trial inv...